RAF/MEK/extracellular signal–related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions

Authors:

Abstract
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia characterized by granulomatous lesions containing pathological CD207+ dendritic cells (DCs) with constitutively activated mitogen-activated protein kinase (MAPK) pathway signaling. Approximately 60% of LCH patients harbor somatic BRAFV600E mutations localizing to CD207+ DCs within lesions. However, the mechanisms driving BRAFV600E+ LCH cell accumulation in lesions remain unknown. Here we show that sustained extracellular signal–related kinase activity induced by BRAFV600E inhibits C-C motif chemokine receptor 7 (CCR7)–mediated DC migration, trapping DCs in tissue lesions. Additionally, BRAFV600E increases expression of BCL2-like protein 1 (BCL2L1) in DCs, resulting in resistance to apoptosis. Pharmacological MAPK inhibition restores migration and apoptosis potential in a mouse LCH model, as well as in primary human LCH cells. We also demonstrate that MEK inhibitor-loaded nanoparticles have the capacity to concentrate drug delivery to phagocytic cells, significantly reducing off-target toxicity. Collectively, our results indicate that MAPK tightly suppresses DC migration and augments DC survival, rendering DCs in LCH lesions trapped and resistant to cell death.
Funding Information
  • HistioCure Foundation
  • National Heart, Lung, and Blood Institute (F31HL126484)
  • National Institutes of Health (2R01CA154947-06A1)
  • National Institutes of Health (CA154489)
  • National Institutes of Health (P50CA126752)
  • National Institutes of Health (CA154947, AI10008, AI089987)
  • German Research Association (BE 4818/1-1, SFBTRR57 P07)
  • St Baldrick’s Foundation
  • Alex’s Lemonade Stand Foundation
  • American Society of Hematology
  • Howard Hughes Medical Institute
  • Dan L. Duncan Cancer Center (P30CA125123)

This publication has 61 references indexed in Scilit: